Abstract: Several guiding principles for treatment of Hepatitis C have been developed by prestigious medical bodies worldwide. However these do not take into consideration about the local availability, technology and infrastructure of developing countries. The objective of this study was to determine the frequency of rapid virological response (RVR) and sustained virological response (SVR) in three categories of naïve, non-responders, and relapsers of HCV patients having genotype 2 and 3 treated with pegylated interferon alpha 2a and ribavirin. Methods: This descriptive clinical study was carried out at multiple places of Pakistan during Jan 2012 to Sep 2014. Hepatitis C patients categorized in three groups of naïve, relapsers, and non-responders treated with Pegylated Interferon alpha 2a 180 µg-40 kD+ribavirin for genotype 2 and 3, for 24 weeks. The primary endpoint was SVR and RVR after 24 weeks. Results: Out of the 1,046 patients, 59.3% were male and 40.7% were female. Mean age of patients was 43.57±6.1 years. HCV genotypes were 3 in 62%, and 2 in 38%. SVR was noticed in 76% naïve patients, 42.8% in non-responders, and 47.9% in relapsers. Conclusion: Pegylated-Interferon alpha 2a 180 µg-40 kD mixed with Ribavirin is clinically helpful and well endured in naïve, relapsers, and non-responders with chronic Hepatitis C.
Keywords: Hepatitis C, treatment naïve, non-responders, relapsers, virological response.
Title: VIROLOGICAL RESPONSE WITH PEGYLATED-INTERFERON ALPHA 2a 180 MICROGRAM-40 KD STUDY
Author: Iftikhar Ali Shah, Masroor Ahmad, Zeeshan Ali, Qurban Shaikh, Neeta Maheshwary, Shaz Effendi, Ahson Siddiqi, Muhammad Athar Khan
International Journal of Life Sciences Research
ISSN 2348-313X (Print), ISSN 2348-3148 (online)
Research Publish Journals
